Abeona Therapeutics (ABEO)
(Delayed Data from NSDQ)
$5.86 USD
-0.16 (-2.66%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $5.85 -0.01 (-0.17%) 5:50 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
ABEO 5.86 -0.16(-2.66%)
Will ABEO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ABEO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ABEO
Philips (PHG) Showcases New AI-Based Solutions at the RSNA
Philips (PHG) to Showcase New Innovations & Cardiac Solutions
ABEO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Philips (PHG) Expands Partnership to Build Angio CT Solution
Philips (PHG) Alerts Users of Health Hazards of Therapy Masks
Ultragenyx's (RARE) Q2 Earnings Miss Estimates, Revenues Up
Other News for ABEO
ABEO Makes Notable Cross Below Critical Moving Average
Biotech Alert: Searches spiking for these stocks today
Abeona Therapeutics Enhances Board with Industry Experts
Abeona Therapeutics appoints Zeiher, Crombez to board of directors
Buy Rating on Abeona Therapeutics Bolstered by Positive Medicare Decisions and FDA Approval Progress